
Pharmaceuticals & Healthcare · NSE
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distribution of pharmaceutical products, including Active Pharmaceutical Ingredients (APIs) and finished formulations in various dosage forms. As of January 31, 2023, the company offers 429 products, with 295 registered in 13 countries and 134 under registration in 16 countries. Remus Pharmaceuticals maintains business-to-business agreements with 58 domestic and 139 international distributors, serving clients across more than 20 countries, including generic distributors, regional distributors, multinational distributors, hospitals, and clinics.
Price Band
₹1150 – ₹1229
Issue Size
₹47.69 Cr
Lot Size
100 shares
GMP
+38.2%
Est. Listing
₹1699
at current GMP
Subscribed
61.53x
overall
Open
17 May 2023
Close
19 May 2023
Allotment
24 May 2023
Refund
25 May 2023
Demat Credit
26 May 2023
Listing
29 May 2023
Last updated: 19 Oct 2026
Current Premium
Issue Price (Upper)
₹1229
Band: ₹1150 – ₹1229
Estimated Listing Price
₹1699
Upper price + GMP
Lot Size
100 shares
Min investment ₹1,22,900
Estimated Profit / Lot
₹47,000
100 × ₹470
Grey Market Premium trend
+₹470
▲ 0 today
Updated less than a minute ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | +₹470 | 38.2% | ₹1699 |
| 30 Oct 2026 | +₹470 | 38.2% | ₹1699 |
| 29 Oct 2026 | +₹423 | 34.4% | ₹1652 |
GMP is unofficial market data. Not a guarantee of listing performance.
Remus Pharmaceuticals Limited is bringing an initial public offering (IPO) in the Pharmaceuticals & Healthcare sector with an aggregate issue size of ₹47.69 Crores. The shares are offered at a price band of ₹1150 to ₹1229 per equity share on NSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 100 shares (approx. ₹1,22,900 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Link Intime India Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2023-05-26, while un-allotted funds or UPI block mandates will be released on 2023-05-25.
The latest grey market premium for Remus Pharmaceuticals Limited IPO is ₹470, which indicates an expected listing price of ₹1699.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.